Financials for the half year and year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vanta Bioscience Limited submitted its audited financial results for FY25 with a significant delay (approved on August 1, 2025 instead of the May 30, 2025 deadline) due to late receipt of accounts from its associate company. On a standalone basis, revenue from operations collapsed to ₹112.74 lakhs from ₹855.79 lakhs in FY24 (a decline of about 87%), and the company swung from a small profit of ₹5.11 lakhs to a net loss of ₹265.95 lakhs. On a consolidated basis (including subsidiaries Vanta Clinical Research and CEBIS India), revenue fell to ₹196.36 lakhs from ₹972.29 lakhs, and the net loss widened sharply to ₹477.49 lakhs from ₹231.59 lakhs. Total borrowings stood at around ₹3,047 lakhs standalone against equity of ₹1,713 lakhs (debt-equity ratio close to 1.8x), and consolidated debt of about ₹7,008 lakhs against equity of just ₹378 lakhs (very high leverage). Consolidated operating cash flow turned negative at ₹(240.86) lakhs compared to positive ₹268.40 lakhs last year. The statutory auditor (M/s Mathesh & Ramana) gave an unmodified, unqualified opinion, and the company reported no defaults on loans.
This is a negative filing for shareholders — revenue has crashed, losses have deepened, leverage is elevated, and operating cash flow turned negative on a consolidated basis. The delay in filing itself is a compliance red flag, though a clean audit opinion provides some reassurance. Expect weak sentiment around the stock.